It's a work in progress as of January 2019. We started by sharing career development insights and would like to expand to other directions based on your input.
By 文：林書弘．圖：陳政儀．編輯：劉駿 on Nov, 2024
在《生技來一刻》第四季第十二集的訪談中，主持人奕芸邀請到了黃正球博士（Joe），現任Eli Lilly神經科學部門的高階主管，來分享他在神經藥物研發領域的經驗與見解。 黃博士擁有豐富的學術背景與業界經歷，從臺灣大學動物系畢業後一路深造，最終在美國加入生技與製藥產業，專注於神經疾病的藥物開發。這次訪談深入探討了神經科學領域的現況與未來趨勢，對生技業界尤其是從事神經科學的聽眾提供了許多寶貴的洞見。 ...Read more
By 文：林書弘．圖：陳政儀．編輯：劉駿 on Apr, 2024
在現今的生技產業中，投資組合管理與數據分析技術的重要性日益增加。尤其在藥物開發這一高風險領域，有效的策略和先進的技術可以顯著提升研發的成功率及市場競爭力。透過近期與羅盈智醫師（Paul）的對話，我們得以深入了解這些策略如何在實際應用中發揮作用。 Paul目前在美國波士頓的 Novartis 藥廠擔任 Portfolio Data Science 部門的副總監，同時也是波士頓台灣醫師協會的會長。他的職業生涯跨越了醫療、人工智慧和商業策略，這使他對於藥廠如何進行投資組合管理有著獨到的見解。 ...Read more
By Yi-Shan Chen on Mar, 2019
As a scientist in Biotech/Pharma, Business Development to me is a function that usually doesn’t have a lot of interaction with researchers unless they need data from you but the decisions they make influence researchers the most. ...Read more
By Yi-ying Chou on Nov, 2018
I always thought that doing biological experiments, like sitting long hours in front of tissue culture hood, can be physically challenging. When I chat with Ryan, I realized that medicinal chemists also have heavy workload on the bench side. In pharmaceutical company, chemists are not allowed to be ...Read more